Healthcare
CSPC Pharmaceuticals Group Ltd.(CHJTF)
Live Price
Offline$0.98
+0.00% today
1Y Change
-6.67%
Window
Jun 25, 2025 โ Jun 23, 2026
- Market Cap
- $95.81B
- Revenue Growth
- -8.7%
- EPS Growth
- -5.1%
- Dividend Yield
- 2.9%
Coverage: 249 bars ยท Jun 25, 2025 โ Jun 23, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
CSPC Pharmaceuticals Group Ltd. (CHJTF) is a Healthcare stock with a market cap of $95.81B and listed on OTC. The stock last traded around $0.98 and down 6.7% across the available one-year price window (Jun 25, 2025 โ Jun 23, 2026). Baseline metrics include revenue growth of -8.7%, EPS growth of -5.1%, a dividend yield of 2.9%. What stands out right now is revenue -8.7%, EPS -5.1%, free cash flow +139.2% with operating margin 15.2% and ROIC 8.4%. The dividend matters to the case here, with a current yield around 2.9%. Valuation is more restrained than many high-expectation growth names at P/E 23.1 and price/sales 3.4. Overall, the current profile looks closer to a turnaround or cyclical reset than a generic broad-market placeholder. Stock Foundry combines CHJTF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Sector Context
How this name stacks up against nearby peers on first-pass metrics.
Revenue Growth
Below sector median
-8.7% vs +7.6% peer median
Operating Margin
Below sector median
+15.2% vs +19.4% peer median
P/E
Below sector median
23.1 vs 36.3 peer median
What Changed This Quarter
Latest report context and the signals most likely to have changed the story.
Latest report is on the board
Q2 2026 was reported on May 26, 2026, but the surprise data is still limited.
The operating picture looks softer than before
Revenue is at -8.7% and EPS is at -5.1%, with operating margin around 15.2%.
Shareholder return is still part of the story
The stock is still offering a dividend yield around 2.9%, which matters if the thesis depends on income as much as growth.
Earnings Reaction Memory
How the stock has tended to move after recent reports.
Across the last 3 reported quarters, the stock averaged 0.0% over the next 5 trading days and finished higher after 0 of those reports.
View quarter-by-quarter reaction table
| Quarter | EPS ฮ | 1D | 5D | 20D |
|---|---|---|---|---|
Q2 2026 May 26, 2026 | โ | +0.0% | +0.0% | โ |
Q2 2026 May 6, 2026 | +6.7% | +0.0% | +0.0% | +0.0% |
Q1 2026 Jan 23, 2026 | +16.1% | +0.0% | +0.0% | +15.0% |
Benchmark Edge
CHJTF vs SPY, QQQ, and Sector ETFs
Normalized return, excess return, max drawdown, and calendar-year wins against the benchmarks investors actually use.
CHJTF
โ
Normalized return
SPY
--
S&P 500
Excess Return
--
Relative to SPY
CHJTF Max Drawdown
-29.50%
Trailing 1Y
SPY Max Drawdown
โ
Trailing 1Y
Calendar-Year Returns
Uses the longest available daily history for CHJTF and SPY.
Company Overview
CSPC Pharmaceuticals Group Ltd.
OTC
CSPC Pharmaceutical Group Ltd. is a prominent entity in the healthcare industry, primarily engaged in the development, production, and distribution of innovative pharmaceuticals. The company's operations span across creating a broad spectrum of pharmaceutical products including antibiotics, cardiovascular therapies, and oncology treatments, addressing both generic and proprietary products. The firm is renowned for its robust research and development capabilities, making significant advancements in biopharmaceutical approaches. CSPC Pharmaceutical Group Ltd. plays a crucial role in enhancing drug accessibility and healthcare solutions, predominantly impacting the healthcare sectors worldwide. With its headquarters situated in China, the company not only serves domestic markets but also extends its influence to global pharmaceutical markets across Asia, Europe, and North America. Its commitment to quality and innovation establishes its significance in the pharmaceutical industry, continuously fostering advancements in medical therapies and patient care solutions. As a key player, CSPC Pharmaceutical Group Ltd. collaborates extensively with research institutions and maintains adherence to international regulatory standards, underscoring its pivotal position in the global healthcare landscape.
- Leadership
- Mr. Cuilong Zhang
- Employees
- 21.4k
- Street Address
- No.896 Zhongshandong Street, Gaoxin District
- Mailing
- Shijiazhuang, 050035
- Region
- Shijiazhuang, China
- Last Updated
- May 7, 2026
Key Fundamentals
Valuation, growth, profitability, and balance sheet signals.
Valuation
- P/E
- 23.1
- EV/EBITDA
- 13.9
- Price/Sales
- 3.4
- Price/Book
- 2.6
Growth
- Revenue
- -8.7%
- EPS
- -5.1%
- Free Cash Flow
- +139.2%
Profitability
- Gross Margin
- 65.6%
- Operating Margin
- 15.2%
- Net Margin
- 14.9%
- ROE
- 12.0%
- ROIC
- 8.4%
Balance Sheet
- Debt/Equity
- 0.02
- Current Ratio
- 2.19
Earnings Reports
Latest News
Official Releases
Company announcements and filings-style updates.
Next Step
Keep the research moving
After the overview, the strongest next step is usually chart context or a tighter compare set.